Search HRGN
Harvard Apparatus Regenerative Technology, Inc.
OTC · CIK 1563665
Last close2.19
Daily change-0.01 (-0.45%)
10 Years gain-89.57%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
HRGN · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
42.5Momentum
100.0Acceleration
100.0Confidence
70.0Annual Revenue13
Quarterly Revenue54
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet0.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 1130.5578 percentage points.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 23.9939 percentage points.
Key Metrics
Revenue Growth TTM158.37%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin6.39%OK
Operating Margin-633.8%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $704,000.00 | $58,000.00 | -$6.92M | -$3.83M | n/a | 8.24% | -982.24% | n/a | -2,477.48% | n/a |
| 2025 FY Dec 31, 2024 | $430,000.00 | $160,000.00 | -$7.73M | -$4.85M | n/a | 37.21% | -1,796.74% | n/a | -1,627.61% | n/a |
| 2024 FY Dec 31, 2023 | $103,000.00 | $79,000.00 | -$8.99M | -$6.94M | -$6.95M | 76.7% | -8,728.16% | -6,747.57% | n/a | n/a |
| 2023 FY Dec 31, 2022 | n/a | $0.00 | -$6.15M | -$5.11M | -$5.11M | n/a | n/a | n/a | n/a | 11.35M |
| 2022 FY Dec 31, 2021 | n/a | $0.00 | -$8.64M | -$2.63M | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.08M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-027566, 0001437749-25-033832 |
| Revenue Growth TTM | 158.37% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-027566, 0001437749-25-033832 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-009079 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-009079 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001437749-26-009079 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027566, 0001437749-25-033832 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 6.39% | Gross Profit / Revenue | OK | 0001437749-26-027566, 0001437749-25-033832 |
| Operating Margin | -633.8% | Operating Income / Revenue | OK | 0001437749-26-027566, 0001437749-25-033832 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-027566 |
| Current Ratio | 0.26x | Current Assets / Current Liabilities | OK | derived |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001437749-26-009079 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001437749-26-027566, 0001437749-25-033832 |